Notice: This company has been marked as potentially delisted and may not be actively trading. Immuron (IMRN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesShort InterestTrends IMRN vs. TNXP, ATNM, SCYX, ITRM, RAPT, BRNS, CALC, ANEB, CASI, and TPSTShould you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Tonix Pharmaceuticals (TNXP), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Iterum Therapeutics (ITRM), RAPT Therapeutics (RAPT), Barinthus Biotherapeutics (BRNS), CalciMedica (CALC), Anebulo Pharmaceuticals (ANEB), CASI Pharmaceuticals (CASI), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical preparations" industry. Immuron vs. Tonix Pharmaceuticals Actinium Pharmaceuticals SCYNEXIS Iterum Therapeutics RAPT Therapeutics Barinthus Biotherapeutics CalciMedica Anebulo Pharmaceuticals CASI Pharmaceuticals Tempest Therapeutics Immuron (NASDAQ:IMRN) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Does the MarketBeat Community favor IMRN or TNXP? Tonix Pharmaceuticals received 152 more outperform votes than Immuron when rated by MarketBeat users. However, 67.87% of users gave Immuron an outperform vote while only 60.93% of users gave Tonix Pharmaceuticals an outperform vote. CompanyUnderperformOutperformImmuronOutperform Votes18867.87% Underperform Votes8932.13% Tonix PharmaceuticalsOutperform Votes34060.93% Underperform Votes21839.07% Is IMRN or TNXP more profitable? Immuron has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Immuron's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ImmuronN/A N/A N/A Tonix Pharmaceuticals -1,197.86%-163.95%-118.88% Does the media prefer IMRN or TNXP? In the previous week, Tonix Pharmaceuticals had 14 more articles in the media than Immuron. MarketBeat recorded 16 mentions for Tonix Pharmaceuticals and 2 mentions for Immuron. Tonix Pharmaceuticals' average media sentiment score of 0.37 beat Immuron's score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Immuron Neutral Tonix Pharmaceuticals Neutral Which has more risk and volatility, IMRN or TNXP? Immuron has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Which has stronger earnings & valuation, IMRN or TNXP? Immuron has higher earnings, but lower revenue than Tonix Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuron$3.21M3.87-$4.55MN/AN/ATonix Pharmaceuticals$7.77M9.02-$116.66M-$52.74-0.01 Do insiders and institutionals believe in IMRN or TNXP? 0.1% of Immuron shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 7.0% of Immuron shares are owned by company insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer IMRN or TNXP? Immuron presently has a consensus target price of $5.00, indicating a potential upside of 133.10%. Tonix Pharmaceuticals has a consensus target price of $53.50, indicating a potential upside of 14,166.67%. Given Tonix Pharmaceuticals' higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Immuron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTonix Pharmaceuticals beats Immuron on 9 of the 15 factors compared between the two stocks. Get Immuron News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRN vs. The Competition Export to ExcelMetricImmuronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.51M$6.92B$5.62B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E RatioN/A10.1189.6917.66Price / Sales3.87351.361,219.4081.09Price / CashN/A65.4844.3437.71Price / Book1.475.335.134.73Net Income-$4.55M$157.56M$118.85M$225.42M Immuron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRNImmuron1.2839 of 5 stars$2.15+7.3%$5.00+133.1%+9.0%$12.51M$3.21M0.00N/AShort Interest ↑TNXPTonix Pharmaceuticals3.0782 of 5 stars$0.24+0.2%$53.50+22,617.6%-95.8%$44.01M$7.77M0.0050Short Interest ↑News CoverageGap UpATNMActinium Pharmaceuticals1.5971 of 5 stars$1.40+14.8%$7.40+428.6%N/A$43.68M$80,000.00-1.0130News CoverageSCYXSCYNEXIS0.9559 of 5 stars$1.12-1.8%N/A-46.7%$42.50M$8.57M-1.5160Positive NewsITRMIterum Therapeutics2.1822 of 5 stars$1.54flat$5.00+224.7%-16.2%$42.38MN/A-0.7710Short Interest ↓Positive NewsRAPTRAPT Therapeutics4.759 of 5 stars$1.20+0.8%$9.56+696.3%-95.5%$41.95M$1.53M-0.4380Short Interest ↓Gap UpBRNSBarinthus Biotherapeutics2.7113 of 5 stars$1.04+3.0%$5.17+396.8%-64.7%$41.84M$800,000.00-0.70107Short Interest ↑CALCCalciMedica3.2859 of 5 stars$3.09-2.5%$19.33+525.7%-62.1%$41.65MN/A-2.8630Short Interest ↓Gap UpANEBAnebulo Pharmaceuticals3.0113 of 5 stars$1.59-1.5%$8.00+403.1%-37.4%$41.23MN/A-5.304Short Interest ↑News CoverageGap UpCASICASI Pharmaceuticals4.5459 of 5 stars$2.62+4.8%$6.00+129.0%-64.4%$40.58M$33.88M-1.17180Analyst ForecastShort Interest ↓Positive NewsGap DownTPSTTempest Therapeutics2.7509 of 5 stars$0.93+3.4%$20.00+2,060.5%-77.0%$40.40MN/A-0.6120Short Interest ↓Positive News Related Companies and Tools Related Companies TNXP Competitors ATNM Competitors SCYX Competitors ITRM Competitors RAPT Competitors BRNS Competitors CALC Competitors ANEB Competitors CASI Competitors TPST Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMRN) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMRN Stock Alerts